AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16633299 — intervention group
Group type: COMPARATOR
Intervention: Oxaliplatin alone (OXA)
Number of subjects: 32
Study 16633299 — intervention group
Group type: COMPARATOR
Intervention: Infusional 5-fluorouracil alone (5-FU)
Number of subjects: 32
Study 14761117 — intervention group
Group type: COMPARATOR
Intervention: Gm (23-) allotype in patients with chronic periodontitis (CP)
Number of subjects: 154
Study 14761117 — intervention group
Group type: EXPERIMENTAL
Intervention: R131 allele of the FcgammaR IIa polymorphisms in generalized aggressive periodontitis (G-AP)
Number of subjects: 154
Study 12791218 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (100,000 IU every 4 months for 5 years)
Number of subjects: 0
Study 10353936 — intervention group
Group type: EXPERIMENTAL
Intervention: Engerix-B vaccine administered at 0-, 1-, and 6-month intervals
Number of subjects: 389
Study 10353936 — intervention group
Group type: COMPARATOR
Intervention: Engerix-B vaccine administered at 0-, 12-, and 24-month intervals
Number of subjects: 389
Study 7564859 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined monochromatic light/laser irradiation at low intensity (660‐950 nm; 31.9 J/cm2; pulsed at 16 Hz)
Number of subjects: 45
Study 7564859 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined monochromatic light/laser irradiation at low intensity (660‐950 nm; 31.9 J/cm2; pulsed at 73 Hz)
Number of subjects: 45
Study 7564859 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition (sham irradiation)
Number of subjects: 45
Study 2014931 — intervention group
Group type: EXPERIMENTAL
Intervention: Bambuterol 20 mg
Number of subjects: 20
Study 2014931 — intervention group
Group type: COMPARATOR
Intervention: Bambuterol 5 mg
Number of subjects: 20
Study 2014931 — intervention group
Group type: COMPARATOR
Intervention: Bambuterol 10 mg
Number of subjects: 20
Study 6213349 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 gm/kg ethanol followed in 1 hr by 1.0 gm IV moxalactam
Number of subjects: 10
Study 6213349 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 gm IV moxalactam every 8 hr for four doses followed by 0.5 gm/kg ethanol
Number of subjects: 10
Study 6213349 — intervention group
Group type: COMPARATOR
Intervention: 0.5 gm/kg ethanol
Number of subjects: 10
Study 4012378 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 60
Study 4012378 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg
Number of subjects: 60
Study 4012378 — intervention group
Group type: COMPARATOR
Intervention: Control (no ranitidine)
Number of subjects: 60
Study 30089447 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed message reminder letter
Number of subjects: 360
Study 30089447 — intervention group
Group type: COMPARATOR
Intervention: Routine reminder letter
Number of subjects: 360
Study 27178746 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrective advertisements with different levels of visual similarity and exposure time delay
Number of subjects: 6454
Study 27178746 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrective advertisements with greater time delay
Number of subjects: 6454
Study 27178746 — intervention group
Group type: COMPARATOR
Intervention: Violative advertisements
Number of subjects: 6454
Study 26088580 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based cognitive behavioral therapy (CBT)
Number of subjects: 214
Study 26088580 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (WL) control
Number of subjects: 214
Study 23625456 — intervention group
Group type: EXPERIMENTAL
Intervention: PATHS curriculum
Number of subjects: 14
Study 23625456 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 14
Study 20178064 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise in water
Number of subjects: 17
Study 20178064 — intervention group
Group type: COMPARATOR
Intervention: Exercise on land
Number of subjects: 17
Study 18509580 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep heating plus stretching
Number of subjects: 30
Study 18509580 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial heating plus stretching
Number of subjects: 30
Study 18509580 — intervention group
Group type: COMPARATOR
Intervention: Stretching alone
Number of subjects: 30
Study 17162414 — intervention group
Group type: EXPERIMENTAL
Intervention: Study pad (formed film top sheet)
Number of subjects: 289
Study 17162414 — intervention group
Group type: COMPARATOR
Intervention: Reference pad (leading nonwoven product)
Number of subjects: 289
Study 14520144 — intervention group
Group type: COMPARATOR
Intervention: Linezolid (outpatient trial)
Number of subjects: 35
Study 14520144 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil (outpatient trial)
Number of subjects: 35
Study 14520144 — intervention group
Group type: COMPARATOR
Intervention: Linezolid (inpatient trial)
Number of subjects: 35
Study 14520144 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin (inpatient trial)
Number of subjects: 35
Study 11155462 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA 300 mg b.i.d. for twelve months
Number of subjects: 36
Study 11155462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 9100711 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 12
Study 9100711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8469914 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol 50/100 mg od
Number of subjects: 100
Study 8469914 — intervention group
Group type: COMPARATOR
Intervention: hydrochlorothiazide 25/50 mg + amiloride 5 mg od (co-amiloride)
Number of subjects: 100
Study 3512620 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal electrical nerve stimulation (TENS)
Number of subjects: 22
Study 26954313 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 3.75%
Number of subjects: 315
Study 26954313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study 24487961 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD640744 (30, 100, and 300 μg doses)
Number of subjects: 49
Study 24487961 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD640744
Number of subjects: 49
Study 22855141 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin plus capecitabine and radiotherapy (RT)
Number of subjects: 46
Study 20728671 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol group assessments
Number of subjects: 135
Study 20728671 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs group assessments
Number of subjects: 135
Study 20728671 — intervention group
Group type: COMPARATOR
Intervention: Control group assessments (normal driving conditions)
Number of subjects: 135
Study 20728671 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents' driving-skills assessments
Number of subjects: 135
Study 20728671 — intervention group
Group type: EXPERIMENTAL
Intervention: Male respondents' self-assessment
Number of subjects: 135
Study 20728671 — intervention group
Group type: EXPERIMENTAL
Intervention: Female respondents' self-assessment
Number of subjects: 135
Study 18988286 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 courses of VABEM (vindesine 5 mg/m², doxorubicin 99 mg/m², carmustine 140 mg/m², etoposide 600 mg/m², methylprednisolone 600 mg/m²) followed by low-dose lymph node irradiation
Number of subjects: 158
Study 18988286 — intervention group
Group type: COMPARATOR
Intervention: 4 cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) followed by myeloablative chemotherapy with carmustine 300 mg/m², etoposide 800 mg/m², cytarabine 1600 mg/m², melphalan 140 mg/m² and autologous stem cell transplantation
Number of subjects: 158
Study 18988286 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 courses of VABEM
Number of subjects: 158
Study 18988286 — intervention group
Group type: COMPARATOR
Intervention: 4 cycles of ABVD
Number of subjects: 158
Study 18988286 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-year FFTF rate for Arm V
Number of subjects: 158
Study 18988286 — intervention group
Group type: COMPARATOR
Intervention: 5-year FFTF rate for Arm A
Number of subjects: 158
Study 18988286 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-year overall survival rate for Arm V
Number of subjects: 158
Study 18988286 — intervention group
Group type: COMPARATOR
Intervention: 5-year overall survival rate for Arm A
Number of subjects: 158
Study 16896509 — intervention group
Group type: EXPERIMENTAL
Intervention: 19-week exercise program
Number of subjects: 0
Study 12792504 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA reduction by 50% over a 2 month period
Number of subjects: 64
Study 12792504 — intervention group
Group type: COMPARATOR
Intervention: Stable-maintenance CsA dose (control group)
Number of subjects: 64
Study 10937426 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied Relaxation (AR)
Number of subjects: 36
Study 10937426 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Therapy (CT)
Number of subjects: 36
Study 9361371 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain aspirin 300 mg
Number of subjects: 0
Study 9361371 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain aspirin 75 mg
Number of subjects: 0
Study 9361371 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric coated aspirin 300 mg
Number of subjects: 0
Study 9361371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1364978 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH (Synacthen) treatment
Number of subjects: 0
Study 4093902 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast self-examination teaching materials (leaflet)
Number of subjects: 0
Study 4093902 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast self-examination teaching materials (tape/slide programme)
Number of subjects: 0
Study 4093902 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of leaflet and tape/slide programme
Number of subjects: 0
Study 31446803 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drug classes (6 classes)
Number of subjects: 4253
Study 31446803 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor 1 (BP pulsatility)
Number of subjects: 4253
Study 31446803 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor 3 (wave reflection)
Number of subjects: 4253
Study 31446803 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor 2 (mean BP)
Number of subjects: 4253
Study 28784096 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge and skills training for mental health professionals about DVA, knowledge and skills training of DVA professionals about mental illness, provision and implementation of a referral pathway between community mental health and DVA services
Number of subjects: 24
Study 28784096 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 24
Study 23969355 — intervention group
Group type: EXPERIMENTAL
Intervention: First Impression (FI) condition
Number of subjects: 393
Study 23969355 — intervention group
Group type: COMPARATOR
Intervention: Directed Search (DS) condition
Number of subjects: 393
Study 18356835 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help (SH) weight loss program
Number of subjects: 54
Study 18356835 — intervention group
Group type: COMPARATOR
Intervention: Therapist-assisted self-help (TASH) weight loss program
Number of subjects: 54
Study 18356835 — intervention group
Group type: COMPARATOR
Intervention: Group-based behavioral weight loss program (BWLP)
Number of subjects: 54
Study 16418281 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavanol-rich cocoa
Number of subjects: 0
Study 16418281 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemically pure (‐)‐epicatechin
Number of subjects: 0
Study 16418281 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic intake of high-flavanol diets
Number of subjects: 0
Study 16418281 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavanol mixture resembling cocoa ingestion profile
Number of subjects: 0
Study 16418281 — intervention group
Group type: COMPARATOR
Intervention: Inhibition of NO synthase
Number of subjects: 0
Study 12731635 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane-remifentanil
Number of subjects: 60
Study 12731635 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane-alfentanil
Number of subjects: 60
Study 10896910 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone with glutamine (mean 0.12 mg/kg/day and oral mean 28 g/day and parenteral mean 5.2 g/day)
Number of subjects: 8
Study 10896910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8826545 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 62
Study 8826545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 1575821 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 9
Study 3908674 — intervention group
Group type: EXPERIMENTAL
Intervention: High-feedback ultrasonography
Number of subjects: 37
Study 3908674 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-feedback ultrasonography
Number of subjects: 37
Study 3908674 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal heart rate monitoring
Number of subjects: 37
Study 3908674 — intervention group
Group type: COMPARATOR
Intervention: Video control
Number of subjects: 37
Study 30066623 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding the concept of brain death
Number of subjects: 1524
Study 30066623 — intervention group
Group type: EXPERIMENTAL
Intervention: Not understanding the concept of brain death
Number of subjects: 1524
Study 30066623 — intervention group
Group type: EXPERIMENTAL
Intervention: Believing brain death does not mean a person’s death
Number of subjects: 1524
Study 30066623 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive attitude toward organ donation
Number of subjects: 1524
Study 30040791 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated 125I seed stents (Test group, n = 13)
Number of subjects: 32
Study 30040791 — intervention group
Group type: COMPARATOR
Intervention: Conventional metal stents (Control group, n = 19)
Number of subjects: 32
Study 30040791 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated 125I seed stents (Test group)
Number of subjects: 32
Study 30040791 — intervention group
Group type: COMPARATOR
Intervention: Conventional metal stents (Control group)
Number of subjects: 32
Study 26888433 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention consisting of 50-minute center-based exercise 2× weekly, augmented with home-based activity to achieve a goal of 150 min/wk of PA
Number of subjects: 1635
Study 26888433 — intervention group
Group type: COMPARATOR
Intervention: Health education intervention consisting of weekly workshops for 26 weeks, and monthly sessions thereafter
Number of subjects: 1635
Study 26888433 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention
Number of subjects: 1635
Study 25125215 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (70 μg daily for 3 months)
Number of subjects: 34
Study 25125215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 22355401 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour secondhand smoke (SHS) exposure at bar/restaurant carbon monoxide levels
Number of subjects: 16
Study 19642060 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic exercise
Number of subjects: 14
Study 19642060 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (no intervention)
Number of subjects: 14
Study 17446643 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-based e-learning
Number of subjects: 96
Study 17446643 — intervention group
Group type: COMPARATOR
Intervention: Structured tutorial
Number of subjects: 96
Study 15157037 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 100
Study 15157037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 9620900 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide (NO) inhalation (7 +/- 1 ppm)
Number of subjects: 10
Study 9620900 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized prostaglandin E1 (PGE1) inhalation (10 +/- 1 ng/kg/min)
Number of subjects: 10
Study 9620900 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of PGE1 (12 +/- 1 ng/kg/min)
Number of subjects: 10
Study 9620900 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 10
Study 9012724 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography as a diagnostic test for women in their 40s with clinical signs requiring follow-up.
Number of subjects: 0
Study 9012724 — intervention group
Group type: COMPARATOR
Intervention: Mammography for women aged 40-49.
Number of subjects: 0
Study 1774431 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HT uptake inhibitors (amitriptyline, clovoxamine, fluvoxamine) for 28 days
Number of subjects: 0
Study 1774431 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic treatment with trazodone or maprotiline (weak inhibitors of platelet 5-HT uptake)
Number of subjects: 0
Study 1774431 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 7018317 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine infiltration after lumbar laminectomy
Number of subjects: 0
Study 7018317 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bupivacaine infiltration)
Number of subjects: 0
Study 31996119 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splint
Number of subjects: 15
Study 31996119 — intervention group
Group type: COMPARATOR
Intervention: Placebo splint
Number of subjects: 15
Study 31996119 — intervention group
Group type: COMPARATOR
Intervention: No splint
Number of subjects: 15
Study 31665578 — intervention group
Group type: EXPERIMENTAL
Intervention: Gilteritinib (120 mg per day)
Number of subjects: 371
Study 31665578 — intervention group
Group type: COMPARATOR
Intervention: Salvage chemotherapy
Number of subjects: 371
Study 29186198 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric citrate (FC)
Number of subjects: 382
Study 29186198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study 23478060 — intervention group
Group type: EXPERIMENTAL
Intervention: R-BEAM (rituximab 375 mg/m² on days -19 and -12, plus carmustine 300 mg/m², etoposide 100 mg/m² twice daily, cytarabine 100 mg/m² twice daily, and melphalan 140 mg/m²)
Number of subjects: 224
Study 23478060 — intervention group
Group type: COMPARATOR
Intervention: B-BEAM (iodine-131 tositumomab dosimetric dose of 5 mCi on day -19 and therapeutic dose of 0.75 Gy on day -12, plus carmustine 300 mg/m², etoposide 100 mg/m² twice daily, cytarabine 100 mg/m² twice daily, and melphalan 140 mg/m²)
Number of subjects: 224
Study 23964468 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturopathic treatment
Number of subjects: 348
Study 23964468 — intervention group
Group type: COMPARATOR
Intervention: Orthopaedic treatment
Number of subjects: 348
Study 19583076 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% (3 mg/kg) + Nitroglycerin (200 microg)
Number of subjects: 46
Study 17241505 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 microg kg(‐1) bolus 10 min before induction plus 0.5 microg kg(‐1) h(‐1) infusions during maintenance
Number of subjects: 40
Study 17241505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16108154 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced sputum analysis
Number of subjects: 0
Study 16108154 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 0
Study 11699169 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (0.2 mg/kg)
Number of subjects: 31
Study 11699169 — intervention group
Group type: COMPARATOR
Intervention: Oral chloral hydrate (62.5 mg/kg) with promethazine (12.5 mg)
Number of subjects: 31
Study 11699169 — intervention group
Group type: COMPARATOR
Intervention: Physiologic parameters (heart rate, blood pressure, respiratory rate, oxygen saturation)
Number of subjects: 31
Study 11699169 — intervention group
Group type: COMPARATOR
Intervention: Behavior assessments (crying, movement, sleep) using the Houpt Sedation Rating Scale
Number of subjects: 31
Study 11699169 — intervention group
Group type: COMPARATOR
Intervention: Modified Vancouver Recovery Scale
Number of subjects: 31
Study 9224438 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (6 mg subcutaneous bolus)
Number of subjects: 16
Study 9224438 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (800 mg orally)
Number of subjects: 16
Study 9224438 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐Dopa (500 mg orally)
Number of subjects: 16
Study 9224438 — intervention group
Group type: EXPERIMENTAL
Intervention: GH‐releasing hormone (GH‐RH 1 microgram/kg body weight i.v. bolus)
Number of subjects: 16
Study 9224438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8118565 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor (500 mg) twice daily for 10 days
Number of subjects: 108
Study 8118565 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (500 mg) three times daily for 10 days
Number of subjects: 108
Study 3729164 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg twice daily for 3 days)
Number of subjects: 2
Study 3729164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 30157946 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D, 4000 IE/day
Number of subjects: 59
Study 30157946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 27351099 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behavior intervention (minimized steps to ≤5000 steps/day for one week)
Number of subjects: 39
Study 27351099 — intervention group
Group type: COMPARATOR
Intervention: Control group (continued normal physical activity levels)
Number of subjects: 39
Study 27351099 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behavior intervention (post-intervention resumption of normal physical activity for one week)
Number of subjects: 39
Study 25120324 — intervention group
Group type: EXPERIMENTAL
Intervention: Early prophylactic (EP) pulmonary surfactant therapy
Number of subjects: 2540
Study 25120324 — intervention group
Group type: COMPARATOR
Intervention: Late selective (LS) pulmonary surfactant therapy
Number of subjects: 2540
Study 22171732 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based brief multiple-health behavior intervention
Number of subjects: 200